Georgetown University/Lombardi Cancer Center

Washington D.C., District of Columbia 20057

2 studies enrolling now · 13 studies all time

What they study most

AML, Acquired Resistance to KRAS G12C Inhibitor, Atypical Hemolytic Uremic Syndrome, BRAF, BRAF Gene Mutation, BRAF Mutation-Related Tumors, BRAF V600 Mutation, BRAF V600E, Brain Metastases, Breast Cancer, Colorectal Cancer, Colorectal Carcinoma

Studies at this site

• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — Recruiting now
• Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy — Completed
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab — Running, not enrolling
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) — Stopped early
• Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma — Completed
• Maintenance Dovitinib for Colorectal and Pancreas Cancer — Stopped early
• Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer — Completed
• Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer — Stopped early
• Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program — Completed
• Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors — Completed
• DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) — Stopped early